氯沙坦對(duì)原發(fā)性高血壓患者纖溶功能的影響(參考版)
2025-01-09 12:03本頁面
【正文】 參考文獻(xiàn)： 【參考文獻(xiàn)】 ［ 1］ Jastrzebskal M， Widecka K， Naruszewicz M, et al. Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor 1 (PAI 1) gene polymorphisms[J]. Nutr Metab Cardiovasc Dis， 2022， 14： 259 269. ［ 2］ Poli KA, Tofler GH, Larson MG, et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population[J]. Circulation,2022,101:264 269. ［ 3］ Selwyn AP, Kinly S, Creager M, et al. Cell dysfunction in atherosclerosis and ischemic manifestations of coronary artery disease[J]. Am J Cardiol, 1997,79(5A):17 23. ［ 4］ Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolyic system as an independent primary risk factor[J]. Circulation. 1998,98:2241 2247. KKME專業(yè)醫(yī)學(xué)搜索引擎 ［ 5］ Papakonstantinou E, Roth M, Kokkas B, et al. Losartan inhibits the angiotensin induced modifications on fibrinolysis and matrixdeposition by primary vascular smooth muscle cells [J]. J Cardiovasc Pharmacol, 2022,38:715 728. ［ 6］ Saito M, Kavasski S, Hasbiba T, et al. Effects of losartan, ang
公司管理相關(guān)推薦
鄂ICP備17016276號(hào)-1